The novel PDE5 inhibitor CPD1 attenuates pulmonary arterial hypertension through dual modulation of cGMP and TRPM8-mediated pathways
Bioorganic Chemistry · 2026-08 · 177 · 109908
DOI: 10.1016/j.bioorg.2026.109908 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-08. Verfasst von Yunping Mu und 9 weiteren Autor:innen. Beteiligte Einrichtung: The School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, Guangdong Province, PR China. Hauptthemen laut MEDLINE: Cyclic GMP, Phosphodiesterase 5 Inhibitors, TRPM Cation Channels, Cyclic Nucleotide Phosphodiesterases, Type 5. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Guangzhou Municipal Science and Technology Program key projects, National Natural Science Foundation of China, Guangdong Provincial Medical Research Foundation.
Abstract (Originalsprache)
Pulmonary arterial hypertension (PAH) remains a fatal condition with limited treatment options. While phosphodiesterase-5 (PDE5) inhibitors such as sildenafil and tadalafil are standard treatments, their therapeutic efficacy is limited by poor aqueous solubility and an incomplete understanding of the mechanisms underlying their long-term benefits on vascular remodeling. To overcome these critical limitations, we developed a novel, highly water-soluble potassium salt polymorph of a PDE5 inhibitor, designated CPD1. In a monocrotaline-induced rat model of PAH, CPD1 demonstrated superior in vivo efficacy. It dose-dependently alleviated key pathological hallmarks by significantly reducing pulmonary arterial pressure, reversing right ventricular hypertrophy, and inhibiting the remodeling of small muscular pulmonary arteries. At the vascular level, CPD1 significantly attenuated the enhanced contractile responses to endothelin-1, cyclopiazonic acid, and 1-oleoyl-2-acetyl-sn-glycerol in endothelium-denuded arteries. Mechanistically, we reveal a novel dual-pathway mechanism: in addition to elevating cyclic guanosine monophosphate (cGMP) through PDE5 inhibition, CPD1 uniquely and dose-dependently upregulates the expression of the transient receptor potential melastatin-8 (TRPM8) channel. This upregulation sensitizes the pulmonary vasculature, markedly enhancing vasodilation induced by TRPM8 activation. Our findings position CPD1 not merely as a more soluble PDE5 inhibitor but as a first-in-class agent that simultaneously modulates the cGMP pathway and the TRPM8 channel, offering a promising new therapeutic strategy to correct dysregulated calcium homeostasis and reverse vascular remodeling in PAH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, Guangdong Province, PR China.
- Hui Ya Hospital of The First Affiliated Hospital, Sun Yat-Sen University, Huizhou, Guangdong Province, PR China.
- Guangzhou Quality Testing & Inspection Institute, Guangzhou, Guangdong Province, PR China.
- The International Translational Medical Research Center, Guangdong Engineering Technology Research Center of Metabolic Disorders Interdisciplinary Precision Prevention and Digital Healthcare, The Eighth Affiliated Hospi…
Förderung
- Guangzhou Municipal Science and Technology Program key projects
- National Natural Science Foundation of China
- Guangdong Provincial Medical Research Foundation
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Major Science and Technology Projects of China
- China Postdoctoral Science Foundation
Zitieren
APA
Mu, Y., Sun, J., Zhang, X., Zhu, H., Li, B., Qiu, H., Zhao, Z., Zhou, S., Li, F., & Zhao, A. Z. (2026). The novel PDE5 inhibitor CPD1 attenuates pulmonary arterial hypertension through dual modulation of cGMP and TRPM8-mediated pathways. Bioorganic Chemistry, 177, 109908. https://doi.org/10.1016/j.bioorg.2026.109908
Vancouver
Mu Y, Sun J, Zhang X, Zhu H, Li B, Qiu H, et al. The novel PDE5 inhibitor CPD1 attenuates pulmonary arterial hypertension through dual modulation of cGMP and TRPM8-mediated pathways. Bioorganic Chemistry. 2026;177:109908. doi:10.1016/j.bioorg.2026.109908
BibTeX
@article{Mu2026,
author = {Mu, Yunping and Sun, Jinlin and Zhang, Xindan and Zhu, Huidan and Li, Bin and Qiu, Haoheng and Zhao, Zhenggang and Zhou, Sujin and Li, Fanghong and Zhao, Allan Zijian},
title = {The novel PDE5 inhibitor CPD1 attenuates pulmonary arterial hypertension through dual modulation of cGMP and TRPM8-mediated pathways},
journal = {Bioorganic Chemistry},
year = {2026},
volume = {177},
pages = {109908},
doi = {10.1016/j.bioorg.2026.109908}
}
EUVIMED